Institution
University of Gothenburg
Education•Gothenburg, Sweden•
About: University of Gothenburg is a education organization based out in Gothenburg, Sweden. It is known for research contribution in the topics: Population & Health care. The organization has 23855 authors who have published 65241 publications receiving 2606327 citations. The organization is also known as: Göteborg University & Gothenburg University.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Evidence suggests that attention to optimum health early in life might benefit cognitive health late in life, and upstream primary prevention has the largest effect on reduction of later dementia occurrence and disability.
Abstract: Summary Dementia is receiving increasing attention from governments and politicians. Epidemiological research based on western European populations done 20 years ago provided key initial evidence for dementia policy making, but these estimates are now out of date because of changes in life expectancy, living conditions, and health profiles. To assess whether dementia occurrence has changed during the past 20–30 years, investigators of five different studies done in western Europe (Sweden [Stockholm and Gothenburg], the Netherlands [Rotterdam], the UK [England], and Spain [Zaragoza]) have compared dementia occurrence using consistent research methods between two timepoints in well-defined geographical areas. Findings from four of the five studies showed non-significant changes in overall dementia occurrence. The only significant reduction in overall prevalence was found in the study done in the UK, powered and designed explicitly from its outset to detect change across generations (decrease in prevalence of 22%; p=0·003). Findings from the study done in Zaragoza (Spain) showed a significant reduction in dementia prevalence in men (43%; p=0·0002). The studies estimating incidence done in Stockholm and Rotterdam reported non-significant reductions. Such reductions could be the outcomes from earlier population-level investments such as improved education and living conditions, and better prevention and treatment of vascular and chronic conditions. This evidence suggests that attention to optimum health early in life might benefit cognitive health late in life. Policy planning and future research should be balanced across primary (policies reducing risk and increasing cognitive reserve), secondary (early detection and screening), and tertiary (once dementia is present) prevention. Each has their place, but upstream primary prevention has the largest effect on reduction of later dementia occurrence and disability.
359 citations
••
TL;DR: Candesartan significantly reduces all-cause mortality, cardiovascular death, and heart failure hospitalizations in patients with CHF and LVEF ≤40% when added to standard therapies including ACE inhibitors, β-blockers, and an aldosterone antagonist.
Abstract: observed for 2 to 4 years (median, 40 months). The primary outcome (time to first event by intention to treat) was cardiovascular death or CHF hospitalization for each trial, with all-cause mortality a secondary end point in the pooled analysis of the low LVEF trials. Of the patients in the candesartan group, 817 (35.7%) experienced cardiovascular death or a CHF hospitalization as compared with 944 (41.3%) in the placebo group (HR 0.82; 95% CI 0.74 to 0.90; P0.001) with reduced risk for both cardiovascular deaths (521 [22.8%] versus 599 [26.2%]; HR 0.84 [95% CI 0.75 to 0.95]; P0.005) and CHF hospitalizations (516 [22.5%] versus 642 [28.1%]; HR 0.76 [95% CI 0.68 to 0.85]; P0.001). It is important to note that all-cause mortality also was significantly reduced by candesartan (642 [28.0%] versus 708 [31.0%]; HR 0.88 [95% CI 0.79 to 0.98]; P0.018). No significant heterogeneity for the beneficial effects of candesartan was found across prespecified and subsequently identified subgroups including treatment with ACE inhibitors, -blockers, an aldosterone antagonist, or their combinations. The study drug was discontinued because of adverse effects by 23.1% of patients in the candesartan group and 18.8% in the placebo group; the reasons included increased creatinine (7.1% versus 3.5%), hypotension (4.2% versus 2.1%), and hyperkalemia (2.8% versus 0.5%), respectively (all P0.001). Conclusion—Candesartan significantly reduces all-cause mortality, cardiovascular death, and heart failure hospitalizations in patients with CHF and LVEF 40% when added to standard therapies including ACE inhibitors, -blockers, and an aldosterone antagonist. Routine monitoring of blood pressure, serum creatinine, and serum potassium is warranted. (Circulation. 2004;110:2618-2626.)
359 citations
••
TL;DR: The challenges associated with the testing of ENPs to generate data on persistence, mobility, bioavailability and ecotoxicity in the environment are discussed and more usable, robust and sensitive methods for characterisation and detection of ENP in environmental systems are developed.
359 citations
••
TL;DR: Plasma tau partly reflects AD pathology, but the overlap between normal aging and AD is large, especially in patients without dementia, and results do not support plasma tau as an AD biomarker in individual people.
Abstract: Objective: To test whether plasma tau is altered in Alzheimer disease (AD) and whether it is related to changes in cognition, CSF biomarkers of AD pathology (including β-amyloid [Aβ] and tau), brain atrophy, and brain metabolism. Methods: This was a study of plasma tau in prospectively followed patients with AD (n = 179), patients with mild cognitive impairment (n = 195), and cognitive healthy controls (n = 189) from the Alzheimer9s Disease Neuroimaging Initiative (ADNI) and cross-sectionally studied patients with AD (n = 61), mild cognitive impairment (n = 212), and subjective cognitive decline (n = 174) and controls (n = 274) from the Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably (BioFINDER) study at Lund University, Sweden. A total of 1284 participants were studied. Associations were tested between plasma tau and diagnosis, CSF biomarkers, MRI measures, 18 fluorodeoxyglucose-PET, and cognition. Results: Higher plasma tau was associated with AD dementia, higher CSF tau, and lower CSF Aβ 42 , but the correlations were weak and differed between ADNI and BioFINDER. Longitudinal analysis in ADNI showed significant associations between plasma tau and worse cognition, more atrophy, and more hypometabolism during follow-up. Conclusions: Plasma tau partly reflects AD pathology, but the overlap between normal aging and AD is large, especially in patients without dementia. Despite group-level differences, these results do not support plasma tau as an AD biomarker in individual people. Future studies may test longitudinal plasma tau measurements in AD.
359 citations
••
TL;DR: The authors explored the ways soldiers in the Congo speak about the massive amount of rape committed by the armed forces in the recent war in the DRC and argued that their explanations of rape must be understood in relation to notions of different (impossible) masculinities.
Abstract: This article explores the ways soldiers in the Congo speak about the massive amount of rape committed by the armed forces in the recent war in the DRC. It focuses on the reasons that the soldiers give to why rape occurs. It discusses how the soldiers distinguish between “lust rapes” and “evil rapes” and argues that their explanations of rape must be understood in relation to notions of different (impossible) masculinities. Ultimately, through reading the soldiers’ words, we can glimpse the logics—arguably informed by the increasingly globalized context of soldiering—through which rape becomes possible, and even “normalized” in particular warscapes.
358 citations
Authors
Showing all 24120 results
Name | H-index | Papers | Citations |
---|---|---|---|
Peter J. Barnes | 194 | 1530 | 166618 |
Luigi Ferrucci | 193 | 1601 | 181199 |
Richard H. Friend | 169 | 1182 | 140032 |
Napoleone Ferrara | 167 | 494 | 140647 |
Timothy A. Springer | 167 | 669 | 122421 |
Anders Björklund | 165 | 769 | 84268 |
Hua Zhang | 163 | 1503 | 116769 |
Kaj Blennow | 160 | 1845 | 116237 |
Leif Groop | 158 | 919 | 136056 |
Tomas Hökfelt | 158 | 1033 | 95979 |
Johan G. Eriksson | 156 | 1257 | 123325 |
Naveed Sattar | 155 | 1326 | 116368 |
Paul Elliott | 153 | 773 | 103839 |
Claude Bouchard | 153 | 1076 | 115307 |
Hakon Hakonarson | 152 | 968 | 101604 |